XML 53 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Revenue from Contracts with Customers (Tables)
 6 Months Ended
Jun. 30, 2019
Revenue from Contracts with Customers [Abstract]  
Disaggregation of Revenue [Table Text Block]
disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and six months ended June 30, 2019 and 2018:
 
 
Three Months Ended
 
Three Months Ended
 
 
June 30, 2019
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
2,203

 
$
3,038

 
$
615

 
$
10,776

Europe
 
705

 
5,454

 
679

 
6,371

Asia
 
3,093

 
1,923

 
1,643

 
8,732

Other
 
66

 
—

 
107

 
—

Total revenue from contracts with customers(1)
 
$
6,067

 
$
10,415

 
$
3,044

 
$
25,879


 
 
Six Months Ended
 
Six Months Ended
 
 
June 30, 2019
 
June 30, 2018
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Medical Devices
 
Pharmaceutical
 
 
 
 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
 
 
 
North America
 
$
4,287

 
$
15,176

 
$
2,319

 
$
21,707

Europe
 
1,722

 
11,036

 
1,294

 
12,362

Asia
 
5,362

 
4,163

 
2,757

 
10,152

Other
 
185

 
—

 
220

 
—

Total revenue from contracts with customers(1)
 
$
11,556

 
$
30,375

 
$
6,590

 
$
44,221

_______________
(1)
The tables above do not include lease revenue from the Company’s Medical Devices segment. For the three-month periods ended June 30, 2019 and 2018, revenue accounted for under Topic 842 and 840, Leases, was $1.4 million and $2.8 million, respectively and for the six-month periods ended June 30, 2019 and 2018 was $2.6 million and $4.3 million, respectively.
Contract with Customer, Asset and Liability [Table Text Block]
The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:
(in thousands)
 
June 30, 2019
 
December 31, 2018
 
 
 
 
 
Receivables, net
 
$
17,872

 
$
20,655

Contract assets
 
$
3,214

 
$
2,595

Contract liabilities
 
$
4,856

 
$
8,938


Receivables, Net—Receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.

Contract assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets in Prepaid and other current assets in the Company’s Condensed Consolidated Balance Sheets based on the timing of when it expects to receive payment.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract assets at December 31, 2018
 
$
—

 
$
2,595

 
$
2,595

Contract assets recognized
 
—

 
4,638

 
4,638

Payments received
 
—

 
(4,019
)
 
(4,019
)
Contract assets at June 30, 2019
 
$
—

 
$
3,214

 
$
3,214


Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.
(in thousands)
 
Medical Devices
 
Pharmaceutical
 
Total
 
 
 
 
 
 
 
Contract liabilities at December 31, 2018
 
$
1,167

 
$
7,771

 
$
8,938

Contract liabilities recognized
 
537

 
2,855

 
3,392

Amounts recognized into revenue
 
(645
)
 
(6,829
)
 
(7,474
)
Contract liabilities at June 30, 2019
 
$
1,059

 
$
3,797

 
$
4,856
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.
 
 
Six Months Ended
 
 
 
 
(in thousands)
 
December 31, 2019
 
Thereafter
 
Total
 
 
 
 
 
 
 
Pharmaceutical product sales
 
$
116

 
$
2,326

 
$
2,442

Medical device sales
 
$
2,347

 
$
3,986

 
$
6,333